PRNewsWire · INSM · October 15, 2026

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

Get the app for more

Explore stock news, insights and company research.